Aptar Pharma, in combination with Schott Glass and EMA Pharmaceuticals, has announced that it will launch Aptar Pharma QuickStart for injectable drug development at CPhI Worldwide 2018, in Madrid today.
Drug development
Aptar Pharma QuickStart is a sterile, Ready-To-Use (RTU) drug development support kit designed specifically for research & development labs. A package complete with glass vials, elastomeric stoppers and caps, the kit also includes all of the quality and technical documentation required to verify the sterilisation and compatibility (CCI) of components. Co-developed alongside Schott and EMA Pharmaceuticals, Aptar Pharma QuickStart is available to cater to different sizes and configurations of vials, stoppers and caps.
CPhI Worldwide, which has started today and lasts until Thursday 11th October 2018 at IFEMA, Feria de Madrid, will welcome more than 45,000 pharma professionals.
Adam Shain, Aptar Pharma’s Director, Global Business Development – Injectables, said: “We are excited to be launching Aptar Pharma QuickStart at CPhI Worldwide, a solution which we are confident will accelerate pharma companies’ bench-to-market.
“QuickStart is all about convenience and speed by enabling R&D labs to maintain a positive development experience from project outset, including the ability to control the component configuration in terms of coating, volume and size, and that the integrity of the container closure for delivery mechanisms can be maintained.”
Luce Sohier, SCHOTT, Business Development commented: “We appreciate that the SCHOTT Topline Vials were chosen to be part of Aptar Pharma QuickStart. We share the vision that enabling our customers to expedite their research is critical. We also see as a real asset that we are providing our customers with the necessary quality documentation for regulatory filing.”
Stefan Greife, Sales Director of EMA Pharmaceuticals added: “We are very proud to be part of this collaboration for the launch of QuickStart, providing our customers with a robust, easy-to-use solution.”